Navigation Links
Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused biopharmaceutical company, today announced that the results from its Phase 2 MEND-CABG trial are featured in a peer reviewed article in the June edition of The Journal of Thoracic and Cardiovascular Surgery, published by the American Association of Thoracic Surgery.

The article, titled, "Effects of pyridoxal-5-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study", outlines evidence of MC-1's potential efficacy in reducing ischemic reperfusion injury. Additionally, the article presents further detail, background information and analysis of Medicure's positive MEND-CABG study.

"We are pleased that our novel cardioprotective product MC-1 is being recognized by one of the leading cardiovascular surgery journals," stated Medicure's President and CEO, Albert D. Friesen, PhD. "The results from MEND-CABG clearly show that patients treated with MC-1 experienced clinically meaningful reductions in the composite endpoint, driven by a pronounced reduction in large non-fatal myocardial infarctions, which comprise the majority of events after CABG surgery. We eagerly anticipate the results of the ongoing pivotal Phase 3 MEND-CABG II registration trial."

Additional Clinical Data

The article also includes new data from a post-hoc analysis demonstrating a statistically significant lower incidence of atrial fibrillation in the MC-1 groups (250 mg @.7% and 750 mg @.0%) compared to the placebo group (11.9%) between post operative day (POD) four and the end of the trial.

"Atrial fibrillation is one of the most common complications after CABG surgery, and is associated with a significant increase in morbidity and mortality, as well as prolonged hospital stay and increased hospital costs," commented Dr. Friesen. "Prevention of atrial fibrilla
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medicure MEND CABG Trial Results Published Peer Reviewed Journal
(Date:6/18/2013)...  Decision Resources, one of the world,s leading ... issues, announces that its Market Access Tracker service ... East and Africa ... opportunities to gaining and maintaining favorable market access ... The countries covered by Market Access Tracker make ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
(Date:6/18/2013)... 18, 2013  Pro football player and 2012 most ... family expert Jo Frost have potentially life-threatening ... the fully integrated specialty pharmaceutical business of Mylan Inc. ... this significant health problem. In recognition of the 25 ... Administration (FDA) approval of EpiPen ® (epinephrine) Auto-Injector, ...
Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8
(Date:6/19/2013)... 19, 2013 The website HealthNewsWires.com has ... resistance, its harmful effects and tips to manage and ... video from HealthNewsWires.com, the author defines insulin resistance ... efficiently remove and process glucose from the bloodstream. ... by all cells, organs and systems of the body ...
(Date:6/19/2013)... Audibel Hearing Center is pleased ... patients, the A2 with Multiflex Tinnitus Technology. Tinnitus ... in the ears. Although bothersome, tinnitus usually isn’t ... , Using their patent-pending Multiflex Tinnitus Technology, the ... sound stimulus that resonates through the patient’s ear. ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Anant Goel, CEO at RKNet Studios ... industrial revolution began in Britain in the late 18th century, ... was born. The second industrial revolution came in the early ... and ushered in the age of mass production. Now a ... is going digital and this could change not just business, ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 On 31 ... the concern about involuntarily detaining patients, a proposal put ... holistic addiction and mental health service provider , The ... apprehension about the suggestion. The centre’s Director and ... assumes those suffering from mental health issues have no ...
Breaking Medicine News(10 mins):Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Involuntary Detention Proposal Dehumanizing, Says Holistic Mental Health Service Provider The Australian Addiction And Trauma Treatment Centre 2Health News:Involuntary Detention Proposal Dehumanizing, Says Holistic Mental Health Service Provider The Australian Addiction And Trauma Treatment Centre 3
... ... tomography examinations underscore the important role that competent, educated CT technologists play in ... , ... Albuquerque, NM (Vocus) December 16, 2009 -- Two recent studies examining radiation doses ...
... , VIRGINIA BEACH, Va., Dec. 17, ... 12 Hampton Roads-area non-profit organizations at its first ,Breakfast ... mistress of ceremonies was local television personality, Barbara Ciara, ... breakfast keynote speaker was world-renowned ,champion, and four-time heavyweight ...
... Dec. 17 Motionsoft, Inc. announced today that it has ... Standards (DSS) certification, making it one of only a handful ... has been granted PCI compliance. , The PCI Standard is ... major credit card companies (Visa International, MasterCard Worldwide, American Express, ...
... , MIAMI, Dec. 17 ... , today announced that it has issued its financial ... financials are being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is ...
... ... Inc. (OTC Bulletin Board: VHGI) confirmed today that VHGI Gold ... for a key advisory board position to assist with evaluating ... a decision for the role and hopes to make an ...
... and glutathione S-transferase T1 (GSTT1) null genotypes have been ... regarding the association between GSTM1 and GSTT1 null genotypes ... However, the majority of previous reports are limited by ... GSTM1/GSTT1 null genotype with the risk of GC and ...
Cached Medicine News:Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 2Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 3Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 3Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 4
... contains primers and a FAM-labeled probe that ... (RSV). In addition, this ASR contains primers ... sample processing control. This ASR requires an ... Red reporter dyes such as the Cepheid ...
... contains primers and a FAM-labeled probe that is ... the Staphylococcus protein A gene. In addition, this ... DNA for an internal control sequence. This ASR ... Texas Red reporter dyes such as the Cepheid ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Reptilase-Time from Bothrops atrox...
Medicine Products: